Major or Mild Neurocognitive Disorder with Lewy Bodies

Clinical picture

• Cognitive fluctuation dominates: episodes of staring, incoherent speech, and daytime drowsiness that families describe as good days and bad days.
• Recurrent well-formed visual hallucinations, typically of people or animals, are often non-threatening and accompanied by preserved insight early on.
• Deficits are attentional, executive, and visuospatial rather than amnestic, so clock drawing and pentagon copying fail well before memory does.
• REM sleep behavior disorder with dream enactment can precede cognitive decline by 10 or more years and is frequently the earliest red flag.
• Parkinsonism is symmetric and bradykinetic with less resting tremor; gait instability and repeated falls are common at first presentation.
• Severe antipsychotic sensitivity, dysautonomia with orthostasis and syncope, constipation, and hyposmia complete the systemic picture.

Criteria snapshot

• Major or mild neurocognitive disorder is established first, then Lewy body etiology is assigned as probable or possible from supporting features.
• Core features are fluctuating cognition with variable attention, recurrent formed visual hallucinations, and spontaneous parkinsonism after cognitive decline.
• Probable diagnosis requires two core features, or one core feature plus a suggestive marker such as REM sleep behavior disorder or low dopamine transporter uptake.
• Onset is insidious with gradual progression, which separates the syndrome from delirium and from abrupt vascular events.
• The one-year rule separates this disorder from Parkinson disease dementia: cognitive decline must begin before or within a year of motor signs.

Neurobiology

• Misfolded alpha-synuclein aggregates as Lewy bodies in brainstem, limbic, and cortical neurons, and most cases also carry Alzheimer copathology.
• Cholinergic loss from nucleus basalis degeneration exceeds that seen in Alzheimer disease and underlies the fluctuations and visual hallucinations.
• Nigrostriatal dopamine loss produces the parkinsonism, and DaTscan shows reduced striatal dopamine transporter uptake with roughly 78% sensitivity.
• Occipital hypometabolism on FDG-PET with a relatively preserved posterior cingulate island sign is a characteristic imaging signature.
• Synuclein pathology in the subcoeruleus abolishes REM atonia, and polysomnography documents REM sleep without atonia underlying dream enactment.
• GBA and SNCA variants raise risk, and cardiac MIBG scintigraphy shows reduced uptake reflecting sympathetic denervation.

Psychology

• Insight is often preserved early, so patients experience genuine distress and shame about hallucinations they can correctly identify as unreal.
• Fluctuating capacity confuses families and clinicians, and lucid intervals are frequently misread as volitional or attention-seeking behavior.
• Visuoperceptual failure generates illusions and misidentification, so patterned wallpaper, mirrors, and low lighting reliably worsen symptoms.
• Depression and apathy affect roughly 40% and are often prodromal, preceding recognized cognitive decline by several years.
• Caregiver burden exceeds that in Alzheimer disease because of falls, dream enactment injury, hallucinations, and unpredictable day-to-day variability.

Differential & comorbidity

• Severe antipsychotic sensitivity occurs in up to 50%: rigidity, immobility, sedation, worsened confusion, and neuroleptic malignant syndrome that can be fatal.
• Avoid haloperidol and every first-generation agent; if psychosis is dangerous, use low-dose quetiapine or clozapine with documented consent.
• Differentiate from Alzheimer disease by early visuospatial and attentional loss, and from Parkinson disease dementia by the one-year rule.
• Delirium mimics the fluctuation, so screen for infection, dehydration, and anticholinergic burden before attributing change to disease progression.
• Comorbid depression, orthostatic hypotension with falls, and constipation are near-universal and drive most avoidable hospitalizations.

Pharmacologic treatment

• Rivastigmine 6-12 mg/day oral or the 9.5 mg/24 h patch is first-line and yields larger gains in cognition and hallucinations than in Alzheimer disease.
• Donepezil 5-10 mg/day is a reasonable alternative; monitor for bradycardia, syncope, gastrointestinal upset, and worsening dream enactment.
• Antipsychotics carry a boxed mortality warning plus severe sensitivity here, so if unavoidable use quetiapine 12.5-100 mg nightly with informed consent.
• Melatonin 3-12 mg at bedtime is first-line for dream enactment, while clonazepam 0.25-1 mg works but adds fall, sedation, and confusion risk.
• Treat parkinsonism cautiously with low-dose carbidopa-levodopa, since dopaminergic agents worsen hallucinations and orthostatic blood pressure drops.

Psychotherapy

• Psychoeducation covering fluctuation, hallucinations, and the danger of antipsychotics is the highest-yield intervention for patient and caregiver alike.
• Hallucination coping strategies include reality testing, distraction, brighter lighting, and removing mirrors and visually ambiguous patterns.
• Cognitive stimulation therapy delivered in roughly 14 group sessions has modest evidence in mild to moderate dementia and is recommended by NICE.
• Adapted CBT or behavioral activation helps depression and anxiety in mild disease when sessions are shortened and heavily externally cued.
• Structured caregiver interventions such as START reduce caregiver depression and delay institutional placement.

Adjunct options

• Make the bedroom safe for dream enactment: lower or pad the bed, clear nightstands, consider separate beds, and secure windows and firearms.
• Manage falls and orthostasis by checking lying and standing pressures, deprescribing antihypertensives, and adding compression, salt, and physical therapy.
• Aggressively remove anticholinergics, benzodiazepines, and sedating antihistamines, which markedly amplify confusion and fluctuation in this population.
• Track cognition with the MoCA and behavior with the Neuropsychiatric Inventory, since informant report captures fluctuation better than office testing.
• Flag antipsychotic sensitivity in the chart and on a medical alert bracelet, and involve palliative care early given the aggressive trajectory.

Clinical pearls

• Neuroleptics can kill in DLB: no haloperidol, ever. Quetiapine or clozapine only, lowest dose.
• Dream enactment plus formed visual hallucinations means DLB until proven otherwise.
• Cholinesterase inhibitors work better here than in Alzheimer disease.